long-term follow-up results of the zuma-1 trial of anti-cd19 car t-cells for non-hodgkin lymphoma
Published 6 years ago • 68 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
2:24
zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl
-
2:43
long-term follow-up results of zuma-5: axi-cel in patients with r/r indolent nhl
-
4:11
interim results of the zuma-12 trial: car t-cell therapy for large b-cell lymphoma
-
6:59
responses to car t-cell therapy still strong after one year in patients with refractory nhl
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
9:41
subcutaneous epcoritamab in r/r b-cell non-hodgkin lymphoma
-
5:31
should immunotherapy stop in responding patients after a fixed duration of treatment?
-
3:31
zuma-1 trial observations
-
1:35
long-term outcomes for patients with ptcl: 10-year follow-up analysis
-
3:07
follow-up car t-cell data so far
-
2:53
autohct in dlbcl in the car-t era
-
6:14
horizon scan of car-t for lymphoma
-
2:26
zuma-5: high orr and cr for r/r inhl with axi-cel
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
8:57
outcomes of sct in t-all and t-lbl
-
1:16
predictors of long-term survival in patients with dlbcl/hgbcl following autosct
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
2:42
results of phase i/ii study of epcoritamab r-dhax/c in patients with r/r dlbcl eligible for autosct
-
3:05
zuma-1, juliet and transcend trials: changing the treatment landscape for r/r nhl
-
4:24
long-term follow-up of a "fast-dc" immunotherapy as a post-remission strategy for aml